Patent · US Active

Modified RNA encoding VEGF-A polypeptides, formulations, and uses relating thereto

US11866475B2 · kind B2 · utility

0Cited by

7References

26Claims

0Family size

Assignee

ModernaTX, Inc. · US

Inventors

Leif Karlsson Parinder · Mölndal, SE
Regina Desirée Fritsche Danielson · Mölndal, SE
Kenny Mikael Hansson · Mölndal, SE
Li Gan · Ebikon, CH
Jonathan Clarke · North York, CA
Ann-Charlotte Eva Egnell · Mölndal, SE
Kenneth R. Chien · Cambridge, US

Key dates

Filing date	Jun 6, 2017
Grant date	Jan 9, 2024
Priority date	—
Expiry date	Jul 6, 2039

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure relates to modified RNA molecules encoding VEGF-A polypeptides and formulations comprising the modified RNA. Aspects of the disclosure further relate to preparations and uses of formulations comprising the modified RNA in treating subjects suffering from diseases responsive to VEGF-A therapy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.